Idiopathic Pulmonary Fibrosis: Pipeline Assessment and Insights
Delivery time for this report is 2-3 days
“Idiopathic Pulmonary Fibrosis: Pipeline Assessment and Insights” report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the Suspended products and outlines in detail the drug profiles of key Pipeline therapies in the disease area.
PIPELINE COVERED:
This section of the report gives the overview of Idiopathic Pulmonary Fibrosis disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Idiopathic Pulmonary Fibrosis disease. Further details on the profile of Idiopathic Pulmonary Fibrosis patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Idiopathic Pulmonary Fibrosis disease.
Pipeline Analysis by Phases, Mechanism of Action and Novelty of Mechanism of Action:
This section of the report highlights and details the key products in development for Idiopathic Pulmonary Fibrosis disease area. The section mentions the products in different phases of development including the NDA/BLA Filing phase, Phase III, Phase II, Phase I, Pre-Clinical phase and the Discovery phase. The section also details the products which have been suspended or terminated during the trial stages of development. The report in this section further highlights the different drugs in pipeline basis on Mechanism of Action of the drug and also on the basis of Novelty of Mechanism of Action of the drug.
DRUGS PROFILE OVERVIEW:
The report, in this section, details all the promising therapies, in Idiopathic Pulmonary Fibrosis disease, in pipeline in different phases of development. The details of a promising drug in pipeline include a detailed overview about the drug in terms of its product details, mechanism of action, mode of administration etc. Further details include the research and development key milestones for the product, detailed information about the efficacy, safety and tolerability and dosage frequency and formulation of the drug. The report also tries to assess the potential clinical and potential commercial positioning of the drug based on the clinical attributes of the drug, trial design, innovator company’s activities in the market and potential perceptions of the drug by physicians and knowledge experts while the drug is still in pipeline.
WHY PURCHASE THE REPORT:
“Idiopathic Pulmonary Fibrosis: Pipeline Assessment and Insights” report delivers an in-depth understanding of the disease, highlights all the pipeline products in different phases of development for the disease including the Suspended products and outlines in detail the drug profiles of key Pipeline therapies in the disease area.
PIPELINE COVERED:
- NDA/BLA Filed
- Phase III Pipeline
- Phase II Pipeline
- Phase I Pipeline
- Preclinical Pipeline
- Discovery Pipeline
- Suspended and Terminated products
- Pipeline analysis by Mechanism of Action
- Pipeline Analysis by Novelty of Mechanism of Action
This section of the report gives the overview of Idiopathic Pulmonary Fibrosis disease indication in detail. The section highlights the basic definition, causes and symptoms of disease and details the types of Idiopathic Pulmonary Fibrosis disease. Further details on the profile of Idiopathic Pulmonary Fibrosis patients, Symptoms experienced by the patients, and disease progression in patients are outlined in the report. The report further highlights the multiple methods through which the patient can be diagnosed for Idiopathic Pulmonary Fibrosis disease.
Pipeline Analysis by Phases, Mechanism of Action and Novelty of Mechanism of Action:
This section of the report highlights and details the key products in development for Idiopathic Pulmonary Fibrosis disease area. The section mentions the products in different phases of development including the NDA/BLA Filing phase, Phase III, Phase II, Phase I, Pre-Clinical phase and the Discovery phase. The section also details the products which have been suspended or terminated during the trial stages of development. The report in this section further highlights the different drugs in pipeline basis on Mechanism of Action of the drug and also on the basis of Novelty of Mechanism of Action of the drug.
DRUGS PROFILE OVERVIEW:
The report, in this section, details all the promising therapies, in Idiopathic Pulmonary Fibrosis disease, in pipeline in different phases of development. The details of a promising drug in pipeline include a detailed overview about the drug in terms of its product details, mechanism of action, mode of administration etc. Further details include the research and development key milestones for the product, detailed information about the efficacy, safety and tolerability and dosage frequency and formulation of the drug. The report also tries to assess the potential clinical and potential commercial positioning of the drug based on the clinical attributes of the drug, trial design, innovator company’s activities in the market and potential perceptions of the drug by physicians and knowledge experts while the drug is still in pipeline.
WHY PURCHASE THE REPORT:
- Detailed description of drugs by phases including pre-clinical and discovery phase
- Detailed description of drugs by Mechanism of Action and Novelty of Mechanism of Action
- Extensive coverage of all the drugs in pipeline
- Coverage of suspended and terminated products along with their phase and reason of suspension
- Coverage for trials across multiple countries
- Detailed drug profiles including Innovator company details, clinical attribute details including efficacy, safety and tolerability and dosage frequency and formulation, trial details, RnD milestones etc.
- Assessment of Clinical and Commercial positioning of the drug based on multiple factors
Table of Contents
1.1 List of Tables
1.2 List of Figures
2 IDIOPATHIC PULMONARY FIBROSIS DISEASE
2.1 Disease Overview
2.1.1 Disease Definition
2.1.2 Disease Epidemiology
2.1.3 Current Treatment Options
2.1.4 Key unmet needs
3 PIPELINE ASSESSMENT
3.1 Overview
3.2 Strategic Review of the Pipeline
3.3 Pipeline analysis by Phases of Development
3.3.1 NDA/BLA Filed
3.3.2 Phase III Pipeline
3.3.3 Phase II Pipeline
3.3.4 Phase I Pipeline
3.3.5 Preclinical Pipeline
3.3.6 Discovery Pipeline
3.4 Pipeline Analysis by Mechanism of Action
3.5 Pipeline Analysis by Novelty of Mechanism of Action
3.6 Suspended and Terminated products
3.7 Idiopathic Pulmonary Fibrosis – Promising Therapies in Pipeline
3.7.1 Pamrevlumab
3.7.1.1 Overview
3.7.1.2 Research & Development Key Milestones
3.7.1.3 Efficacy
3.7.1.4 Safety
3.7.1.5 Dosing Frequency and Formulation
3.7.1.6 Potential Clinical Positioning
3.7.1.7 Potential Commercial Positioning
3.7.1.8 Pricing and Reimbursement
3.7.2 MN-001
3.7.2.1 Overview
3.7.2.2 Research and development key milestones
3.7.2.3 Efficacy
3.7.2.4 Safety
3.7.2.5 Dosing Frequency and Formulation
3.7.2.6 Potential Clinical Positioning
3.7.2.7 Potential Commercial Positioning
3.7.2.8 Pricing and Reimbursement
3.7.3 GLPG1690
3.7.3.1 Overview
3.7.3.2 Research and development key milestones
3.7.3.3 Efficacy
3.7.3.4 Safety
3.7.3.5 Dosing Frequency and Formulation
3.7.3.6 Potential Clinical Positioning
3.7.3.7 Potential Commercial Positioning
3.7.3.8 Pricing and Reimbursement
3.7.4 Lebrikizumab
3.7.4.1 Overview
3.7.4.2 Research and development key milestones
3.7.4.3 Efficacy
3.7.4.4 Safety
3.7.4.5 Dosing Frequency and Formulation
3.7.4.6 Potential Clinical Positioning
3.7.4.7 Potential Commercial Positioning
3.7.4.8 Pricing and Reimbursement
3.7.5 MK-7264
3.7.5.1 Overview
3.7.5.2 Research and development key milestones
3.7.5.3 Efficacy
3.7.5.4 Safety
3.7.5.5 Dosing Frequency and Formulation
3.7.5.6 Potential Clinical Positioning
3.7.5.7 Potential Commercial Positioning
3.7.5.8 Pricing and Reimbursement
3.7.6 TD139
3.7.6.1 Overview
3.7.6.2 Research and development key milestones
3.7.6.3 Efficacy
3.7.6.4 Safety
3.7.6.5 Dosing Frequency and Formulation
3.7.6.6 Potential Clinical Positioning
3.7.6.7 Potential Commercial Positioning
3.7.6.8 Pricing and Reimbursement
3.7.7 PBI-4050
3.7.7.1 Overview
3.7.7.2 Research and development key milestones
3.7.7.3 Efficacy
3.7.7.4 Safety
3.7.7.5 Dosing Frequency and Formulation
3.7.7.6 Potential Clinical Positioning
3.7.7.7 Potential Commercial Positioning
3.7.7.8 Pricing and Reimbursement
3.7.8 PRM-151
3.7.8.1 Overview
3.7.8.2 Research and development key milestones
3.7.8.3 Efficacy
3.7.8.4 Safety
3.7.8.5 Dosing Frequency and Formulation
3.7.8.6 Potential Clinical Positioning
3.7.8.7 Potential Commercial Positioning
3.7.8.8 Pricing and Reimbursement
4 APPENDIX
4.1 Coverage
4.2 Methodology and Research conducted
4.3 About Pharmascroll
4.4 Contact Us
4.5 Disclaimer
1.1 List of Tables
1.2 List of Figures
2 IDIOPATHIC PULMONARY FIBROSIS DISEASE
2.1 Disease Overview
2.1.1 Disease Definition
2.1.2 Disease Epidemiology
2.1.3 Current Treatment Options
2.1.4 Key unmet needs
3 PIPELINE ASSESSMENT
3.1 Overview
3.2 Strategic Review of the Pipeline
3.3 Pipeline analysis by Phases of Development
3.3.1 NDA/BLA Filed
3.3.2 Phase III Pipeline
3.3.3 Phase II Pipeline
3.3.4 Phase I Pipeline
3.3.5 Preclinical Pipeline
3.3.6 Discovery Pipeline
3.4 Pipeline Analysis by Mechanism of Action
3.5 Pipeline Analysis by Novelty of Mechanism of Action
3.6 Suspended and Terminated products
3.7 Idiopathic Pulmonary Fibrosis – Promising Therapies in Pipeline
3.7.1 Pamrevlumab
3.7.1.1 Overview
3.7.1.2 Research & Development Key Milestones
3.7.1.3 Efficacy
3.7.1.4 Safety
3.7.1.5 Dosing Frequency and Formulation
3.7.1.6 Potential Clinical Positioning
3.7.1.7 Potential Commercial Positioning
3.7.1.8 Pricing and Reimbursement
3.7.2 MN-001
3.7.2.1 Overview
3.7.2.2 Research and development key milestones
3.7.2.3 Efficacy
3.7.2.4 Safety
3.7.2.5 Dosing Frequency and Formulation
3.7.2.6 Potential Clinical Positioning
3.7.2.7 Potential Commercial Positioning
3.7.2.8 Pricing and Reimbursement
3.7.3 GLPG1690
3.7.3.1 Overview
3.7.3.2 Research and development key milestones
3.7.3.3 Efficacy
3.7.3.4 Safety
3.7.3.5 Dosing Frequency and Formulation
3.7.3.6 Potential Clinical Positioning
3.7.3.7 Potential Commercial Positioning
3.7.3.8 Pricing and Reimbursement
3.7.4 Lebrikizumab
3.7.4.1 Overview
3.7.4.2 Research and development key milestones
3.7.4.3 Efficacy
3.7.4.4 Safety
3.7.4.5 Dosing Frequency and Formulation
3.7.4.6 Potential Clinical Positioning
3.7.4.7 Potential Commercial Positioning
3.7.4.8 Pricing and Reimbursement
3.7.5 MK-7264
3.7.5.1 Overview
3.7.5.2 Research and development key milestones
3.7.5.3 Efficacy
3.7.5.4 Safety
3.7.5.5 Dosing Frequency and Formulation
3.7.5.6 Potential Clinical Positioning
3.7.5.7 Potential Commercial Positioning
3.7.5.8 Pricing and Reimbursement
3.7.6 TD139
3.7.6.1 Overview
3.7.6.2 Research and development key milestones
3.7.6.3 Efficacy
3.7.6.4 Safety
3.7.6.5 Dosing Frequency and Formulation
3.7.6.6 Potential Clinical Positioning
3.7.6.7 Potential Commercial Positioning
3.7.6.8 Pricing and Reimbursement
3.7.7 PBI-4050
3.7.7.1 Overview
3.7.7.2 Research and development key milestones
3.7.7.3 Efficacy
3.7.7.4 Safety
3.7.7.5 Dosing Frequency and Formulation
3.7.7.6 Potential Clinical Positioning
3.7.7.7 Potential Commercial Positioning
3.7.7.8 Pricing and Reimbursement
3.7.8 PRM-151
3.7.8.1 Overview
3.7.8.2 Research and development key milestones
3.7.8.3 Efficacy
3.7.8.4 Safety
3.7.8.5 Dosing Frequency and Formulation
3.7.8.6 Potential Clinical Positioning
3.7.8.7 Potential Commercial Positioning
3.7.8.8 Pricing and Reimbursement
4 APPENDIX
4.1 Coverage
4.2 Methodology and Research conducted
4.3 About Pharmascroll
4.4 Contact Us
4.5 Disclaimer
